Director Luke Evnin reported selling shares of Werewolf Therapeutics Inc (NASDAQ:HOWL) between December 2nd and December 4th, 2025. The sales, executed under a prearranged 10b5-1 trading plan, totaled ...
Additionally, Citizens has reiterated its Market Outperform rating for Werewolf Therapeutics, maintaining a price target of $3.00. The rating follows the company’s recent presentation of preclinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback